{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:42:54Z","timestamp":1792712574390,"version":"4.5.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoints inhibitors have transformed the prognosis of advanced melanoma but are associated with immune-related adverse events (irAEs). We evaluated the incidence, risk factors and causes of acute kidney injury (AKI) in a monocentric real-life cohort of patients treated with anti-programmed death receptor-1 (anti-PD1) antibodies for advanced melanoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective collection of medical charts and comprehensive analysis of lab results from patients treated with nivolumab or pembrolizumab for advanced melanoma between 2014 and 2018 was carried out. AKI was defined by Kidney Disease Improving Global Outcomes criteria, and causes were determined by chart review. Overall survival, survival without AKI and impact of AKI on survival were analysed. Risk factors for death and for AKI were identified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Two hundred and thirty-nine patients were included. Forty-one (17%) had at least one episode of AKI. Independent risk factors for AKI were treatment with renin\u2013angiotensin\u2013aldosterone system inhibitors (RAASi), pre-existing chronic kidney disease (CKD) and cumulated doses of anti-PD1. The main cause of AKI was prerenal, and only eight patients (3.3%) developed acute interstitial nephritis; 8% of patients developed CKD. The median overall survival was 13.4\u2009months and was not affected by AKI. In multivariate analysis, the overall mortality was lower in overweight and obese patients and higher in patients treated with proton-pump inhibitors (PPI) or corticosteroids.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>AKI is common in patients treated with anti-PD1 for advanced melanoma but is mostly prerenal and favoured by the use of RAASi; renal irAE is rare. PPI and corticosteroids were associated with poor survival in this population, while overweight\/obesity was protective.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfaa137","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T11:34:54Z","timestamp":1589456094000},"page":"1664-1674","source":"Crossref","is-referenced-by-count":61,"title":["Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort"],"prefix":"10.1093","volume":"36","author":[{"given":"Claire","family":"Stein","sequence":"first","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille, Centre de N\u00e9phrologie et Transplantation R\u00e9nale, H\u00f4pital de la Conception, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Burtey","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille, Centre de N\u00e9phrologie et Transplantation R\u00e9nale, H\u00f4pital de la Conception, Marseille, France"},{"name":"Aix-Marseille University, INSERM 1263, INRAE 1260, Centre de recherche en CardioVasculaire et Nutrition, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mancini","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille, Sant\u00e9 Publique, H\u00f4pital de la Timone, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille, Centre de N\u00e9phrologie et Transplantation R\u00e9nale, H\u00f4pital de la Conception, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Sall\u00e9e","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille, Centre de N\u00e9phrologie et Transplantation R\u00e9nale, H\u00f4pital de la Conception, Marseille, France"},{"name":"Aix-Marseille University, INSERM 1263, INRAE 1260, Centre de recherche en CardioVasculaire et Nutrition, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Brunet","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille, Centre de N\u00e9phrologie et Transplantation R\u00e9nale, H\u00f4pital de la Conception, Marseille, France"},{"name":"Aix-Marseille University, INSERM 1263, INRAE 1260, Centre de recherche en CardioVasculaire et Nutrition, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Berbis","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille, Centre de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie, H\u00f4pital Nord, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Jacques","family":"Grob","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille, Centre de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie et Canc\u00e9rologie Cutan\u00e9e, H\u00f4pital de la Timone, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Honor\u00e9","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille, Onco-Pharmacie, H\u00f4pital de la Timone, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gaudy","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille, Centre de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie et Canc\u00e9rologie Cutan\u00e9e, H\u00f4pital de la Timone, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9315-1577","authenticated-orcid":false,"given":"No\u00e9mie","family":"Jourde-Chiche","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille, Centre de N\u00e9phrologie et Transplantation R\u00e9nale, H\u00f4pital de la Conception, Marseille, France"},{"name":"Aix-Marseille University, INSERM 1263, INRAE 1260, Centre de recherche en CardioVasculaire et Nutrition, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"key":"2021082722455679200_OP-B1"},{"key":"2021082722455679200_OP-B2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-017-0458-3","article-title":"The use of immunotherapy in the treatment of melanoma","volume":"10","author":"Achkar","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2021082722455679200_OP-B3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5114\/wo.2018.73889","article-title":"Immunotherapy of melanoma","volume":"22","author":"Lugowska","year":"2018","journal-title":"Wsp\u00f3lczesna Onkol"},{"key":"2021082722455679200_OP-B4","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s40265-014-0314-5","article-title":"Pembrolizumab: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"2021082722455679200_OP-B5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021082722455679200_OP-B6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","article-title":"Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials","volume":"1","author":"Larkin","year":"2015","journal-title":"JAMA Oncol"},{"key":"2021082722455679200_OP-B7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"2021082722455679200_OP-B8","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021082722455679200_OP-B9","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"2021082722455679200_OP-B10","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"2021082722455679200_OP-B11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021082722455679200_OP-B12","first-page":"8: 730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"2021082722455679200_OP-B13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"2021082722455679200_OP-B14","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021082722455679200_OP-B15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s13054-016-1478-z","article-title":"Acute kidney injury 2016: diagnosis and diagnostic workup","volume":"20","author":"Ostermann","year":"2016","journal-title":"Crit Care"},{"key":"2021082722455679200_OP-B16","first-page":"c179","volume-title":"Nephron Clin Pract"},{"key":"2021082722455679200_OP-B17","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","article-title":"Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions","volume":"55","author":"Levey","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2021082722455679200_OP-B18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"2021082722455679200_OP-B19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.nephro.2018.07.004","article-title":"NToxicit\u00e9 r\u00e9nale des immunoth\u00e9rapies: r\u00e9sultats pr\u00e9liminaires de l\u2019\u00e9tude ImmuNoTox","volume":"14","author":"Espi","year":"2018","journal-title":"N\u00e9phrol Th\u00e9rapeutique"},{"key":"2021082722455679200_OP-B20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1634\/theoncologist.2018-0764","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated renal toxicity: illustrative case and review","volume":"24","author":"Sise","year":"2019","journal-title":"Oncologist"},{"key":"2021082722455679200_OP-B21","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"2021082722455679200_OP-B22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2021082722455679200_OP-B23","first-page":"936","article-title":"Renal effects of immune checkpoint inhibitors","volume":"32","author":"Izzedine","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2021082722455679200_OP-B24","first-page":"17: 188","article-title":"Nivolumab-associated acute glomerulonephritis: a case report and literature review","author":"Jung","year":"2016","journal-title":"BMC Nephrol"},{"key":"2021082722455679200_OP-B25","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","article-title":"IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma","volume":"57","author":"Kishi","year":"2018","journal-title":"Intern Med"},{"key":"2021082722455679200_OP-B26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/CJI.0000000000000189","article-title":"Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report","volume":"40","author":"Daanen","year":"2017","journal-title":"J Immunother"},{"key":"2021082722455679200_OP-B27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2021082722455679200_OP-B28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2018","journal-title":"Clin Kidney J"},{"key":"2021082722455679200_OP-B29","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11523-016-0426-9","article-title":"Severe hyponatremia and immune nephritis following an initial infusion of Nivolumab","volume":"11","author":"Vandiver","year":"2016","journal-title":"Targ Oncol"},{"key":"2021082722455679200_OP-B30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.currproblcancer.2016.12.004","article-title":"Renal complications of immune checkpoint blockade","volume":"41","author":"Murakami","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"2021082722455679200_OP-B31"},{"key":"2021082722455679200_OP-B32","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ekir.2017.02.008","article-title":"Anticancer drug-induced acute kidney injury","volume":"2","author":"Izzedine","year":"2017","journal-title":"Kidney Int Rep"},{"key":"2021082722455679200_OP-B33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2016.07.026","article-title":"Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient","volume":"67","author":"Herz","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021082722455679200_OP-B34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2018.02.007","article-title":"Immune checkpoint therapy in proteinuric kidney disease","volume":"95","author":"Takenaka","year":"2018","journal-title":"Eur J Cancer"},{"key":"2021082722455679200_OP-B35","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: past, present and future","volume":"29","author":"Perazella","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2021082722455679200_OP-B36","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1634\/theoncologist.2016-0450","article-title":"Impact of age on outcomes with immunotherapy for patients with melanoma","volume":"22","author":"Betof","year":"2017","journal-title":"Oncologist"},{"key":"2021082722455679200_OP-B37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"The association of BMI and outcomes in metastatic melanoma: a retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021082722455679200_OP-B38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.coi.2018.03.012","article-title":"Obesity induced T cell dysfunction and implications for cancer immunotherapy","volume":"51","author":"Aguilar","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"2021082722455679200_OP-B39","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/JLB.5RI1017-401RR","article-title":"Obesity as an immune-modifying factor in cancer immunotherapy","volume":"104","author":"Canter","year":"2018","journal-title":"J Leukoc Biol"},{"key":"2021082722455679200_OP-B40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s13679-015-0152-0","article-title":"Gut microbiome and obesity: a plausible explanation for obesity","volume":"4","author":"Sanmiguel","year":"2015","journal-title":"Curr Obes Rep"},{"key":"2021082722455679200_OP-B41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1051\/medsci\/20163205012","article-title":"Alteration of intestinal permeability: the missing link between gut microbiota modifications and inflammation in obesity?","volume":"32","author":"Genser","year":"2016","journal-title":"Med Sci (Paris)"},{"key":"2021082722455679200_OP-B42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"2021082722455679200_OP-B43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"2021082722455679200_OP-B44","article-title":"Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients","volume":"29 (Suppl 10): x39\u2013x43","author":"Homicsko","year":"2018","journal-title":"Ann Oncol"},{"key":"2021082722455679200_OP-B45","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021082722455679200_OP-B46","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Early use of systemic corticosteroids in patients with advanced NSCLC treated with Nivolumab","volume":"13","author":"Scott","journal-title":"J Thorac Oncol"},{"key":"2021082722455679200_OP-B47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/9\/1664\/40075862\/gfaa137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/9\/1664\/40075862\/gfaa137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T22:47:06Z","timestamp":1630104426000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/36\/9\/1664\/5907972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,17]]},"published-print":{"date-parts":[[2021,8,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa137","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2020,9,17]]}}}